PARI Pharma GmbH is part of the PARI Group and focuses on medicinal products and inhalation devices using eFlow technology. The company also develops optimized drug-device combinations through licensing partnerships.
Savara has submitted a Biologics License Application for MOLBREEVI to the FDA with Priority Review status, targeting an August 22, 2026 decision date for treating autoimmune pulmonary alveolar proteinosis.
Savara Inc. announced the FDA has filed for review the BLA for MOLBREEVI to treat autoimmune PAP, granting Priority Review with a PDUFA action date of August 22, 2026. The therapy could become the first approved treatment for this rare lung disease.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06134401 |
Nebulised Hypertonic Saline to Decrease Respiratory Exacerbations in Neuromuscular Disease or Neurodisability |
NOT_YET_RECRUITING | NA |
| NCT04176328 |
Open-label, Dose-escalation Study to Evaluate the Pharmacokinetics of Inhaled Teicoplanin in Cystic Fibrosis Patients |
COMPLETED | PHASE1 |
| NCT01955980 |
Buparid/PARI SINUS Versus Budes® Nasal Spray in the Therapy of Chronic Rhinosinusitis |
COMPLETED | PHASE1/PHASE2 |
| NCT01953367 |
Bioequivalence and Safety of Vantobra and TOBI in Healthy Subjects |
COMPLETED | PHASE1 |
| NCT01946711 |
Buparid/PARI SINUS Versus Budes® Nasal Spray in the Therapy of Chronic Rhinosinusitis With Polyposis Nasi |
COMPLETED | PHASE1/PHASE2 |
| NCT01439958 |
Long-term Safety Follow-up Study in the Prevention of Bronchiolitis Obliterans Syndrome (BOS) |
TERMINATED | PHASE3 |
| NCT01334892 |
L-CsA in the Prevention of Bronchiolitis Obliterans Syndrome (BOS) in Lung Transplant (LT) Patients |
TERMINATED | PHASE2/PHASE3 |
